Phase 2 Pancreatic Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People aged 18 to 80 years old
- People whose general health and ability to carry out daily activities meets a certain standard, as measured by a medical scoring tool called the ECOG scale (score of 2 or below, meaning the person is able to be up and about for at least half of the day)
- People who have been confirmed through a tissue or fluid sample to have pancreatic cancer of a specific type called adenocarcinoma
- People whose blood test results show healthy enough levels of white blood cells, infection-fighting cells (neutrophils), and platelets (cells that help blood clot)
- People whose kidney function is within an acceptable range based on a blood test
- People whose cancer has spread only to the lining of the abdominal cavity (the peritoneum), which may be seen on scans or confirmed through fluid samples or a surgical procedure
- People who have already completed pre-surgery chemotherapy and whose cancer has shown a meaningful response — such as a greater than 50% drop in a tumour marker called CA 19-9, or improvement shown on scans
- People whose spread to the abdominal lining is limited (scored 7 or below on a medical index called the PCI), and where the surgeon considers it very likely that all visible cancer can be surgically removed
Who may not be able to join:
- People whose cancer has spread to solid organs such as the liver, lungs, or brain
- People who have an active infection, such as pneumonia or a wound infection, that could interfere with treatment
- Women who have a positive pregnancy test (urine or blood), or women who could become pregnant and are not willing or able to use reliable contraception and avoid breastfeeding during the study
- People who the medical team believes would not be able to follow the study requirements or attend follow-up appointments
- People who have previously had a serious allergic reaction to the chemotherapy used in this study — for example, a reaction that was life-threatening, required a hospital stay, or caused lasting physical harm
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Cornelius A. Thiels, DO, MBA, Mayo Clinic in Rochester
Phone: 855-776-0015
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall survival; Progression-free survival
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.